Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares. The filing date is June 26, 2025, covering share repurchases executed on June 25, 2025. The Company is a Foreign Private Issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a specific block of share buybacks executed as part of an existing program. No revenue, profit, or cash flow data is provided in this specific filing.
- Shares Purchased (June 25, 2025): 483,629 ordinary shares.
- Price Range: Lowest 1,395.00p; Highest 1,411.00p.
- Volume-Weighted Average Price (VWAP): 1,400.74p.
- Trading Venue: London Stock Exchange (XLON).
- Broker: Merrill Lynch International.
- Treasury Shares Held: 224,721,591 (post-transaction).
- Shares in Issue (excluding Treasury): 4,090,623,881.
- Voting Rights in Treasury: 5.49%.
Material Changes and Program Progress
The purchase on June 25, 2025, was effected pursuant to a non-discretionary agreement entered into with the broker on June 4, 2025. Since the inception of this specific agreement on June 4, 2025, the Company has purchased an aggregate of 6,587,208 ordinary shares. The filing confirms the updated total of treasury shares and the corresponding percentage of voting rights attributable to those shares.
Guidance, Outlook, and Risks
This filing contains no management commentary, financial guidance, or outlook. It is a regulatory disclosure of a completed share transaction. The filing notes that the purchased shares will be held as Treasury shares. No specific risks or contingencies are discussed beyond the standard regulatory context of the buyback program.
Investor Verification Checklist
- Verify the total number of shares purchased under the non-discretionary agreement since June 4, 2025 (stated as 6,587,208).
- Confirm the updated total of treasury shares held (224,721,591) and the resulting voting rights percentage (5.49%).
- Review the aggregate number of ordinary shares in issue excluding treasury shares (4,090,623,881) for denominator calculations regarding disclosure thresholds.
- Check the VWAP of 1,400.74p against the market price on June 25, 2025, to assess execution efficiency.